Licensee Quark Pharmaceuticals announces positive Phase 2 data in Acute Kidney Injury

Licensee Quark Pharmaceuticals announces positive Phase 2 data in Acute Kidney Injury 27 July 2017 Silence Therapeutics plc, AIM:SLN (“Silence” or “the Company”) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, notes Quark Pharmaceutical, Inc’s (“Quark”) press release “Quark Pharmaceuticals Reports Positive Results from a Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury (AKI) in Subjects at High Risk of AKI Following Cardiac Surgery”. Quark reported that the trial’s primary endpoint and multiple secondary endpoints were met. Quark holds a licence to Silence’s chemical modification technology. Silence is eligible to receive either approximately 2% royalties from Quark (on QPI -1002) plus milestones, or 15% of the clinical, regulatory and commercial milestone payments and royalties received by Quark from its partner Novartis. Quark’s full announcement can be found here: http://quarkpharma.com/?p=12442. Enquiries: Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer Tel: +44 (0)20 3457 6900 Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson Tel: +44 (0)20 7418 8900 Media Enquiries: FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert Tel: +44 (0) 20 3727 1000 Notes to Editors About Silence Therapeutics plc Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease -causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

The release as fetched from its publisher. silence-therapeutics.com ↗